2015-2019 年医疗保险部分 D 中粒细胞集落刺激因子和英夫利昔单抗生物类似药的使用情况。
Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019.
机构信息
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland.
Masonic Cancer Center, University of Minnesota, Minneapolis.
出版信息
JAMA Netw Open. 2022 Mar 1;5(3):e221117. doi: 10.1001/jamanetworkopen.2022.1117.
Abstract
This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D.
摘要
本横断面研究考察了非格司亭和英夫利昔单抗产品及其生物类似药的使用趋势，以了解生物类似药是否与医疗保险部分 D 支出减少有关。
Zotero 插件